MEC-1 Cells

The MEC-1 cell line is derived from a patient with chronic lymphocytic leukemia (CLL) in the prolymphocytoid transformation stage. It serves as a critical model for investigating the biology of B-cell malignancies, particularly the molecular mechanisms underpinning CLL and its responses to therapies. MEC-1 cells are characterized by the expression of CD19 and CD5 markers, consistent with their origin in CLL, and they are widely used to study the mechanisms of chemoresistance and metabolic adaptations in leukemia.

Research utilizing MEC-1 cells has provided insights into the interplay between the tumor microenvironment and leukemia cell survival. For instance, this cell line has been instrumental in identifying mechanisms of resistance to targeted therapies, such as the Bcl-2 antagonist venetoclax. In resistant MEC-1 derivatives (MEC-1 VER), overexpression of p38 MAPK and alterations in pro-apoptotic and anti-apoptotic protein expression have been observed. This highlights the potential of targeting pathways like p38 MAPK and the immunoproteasome to overcome drug resistance.

Under hypoxic conditions, MEC-1 cells exhibit metabolic reprogramming that supports their survival and proliferation. This adaptation involves increased expression of glucose transporters like GLUT1 and GLUT3, as well as shifts in glycolysis and lactate production, which are regulated by hypoxia-inducible factors (HIFs). Additionally, studies involving CRISPR/Cas9-mediated deletion of specific microRNAs, such as miR-155, have revealed their role in regulating MEC-1 cell metabolism and proliferation under hypoxic stress, providing further avenues for therapeutic intervention.